Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 425-427

  Etherington, Christine ^a   Hall, Melanie ^b   Conway, Steven ^a   Peckham, Daniel ^a   Denton, Miles ^b  

^a SEACROFT HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Efficiency; Laboratory; Processing; Respiratory

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; C REACTIVE PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL PROTOCOL; COST CONTROL; CYSTIC FIBROSIS; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 38349101876     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm481     Document Type: Article

References (10)

1. Doring G, Conway SP, Heijerman HGM et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000; 16: 749-67.
2. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001; 120: 118S-23S.
3. Smith AL, Fiel SB, Mayer-Hamblett N et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.
4. Foweraker JE, Laughton CR, Brown DFJ et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55: 921-7.
5. Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 2005; 43: 5085-90.
6. Lee TWR, Brownlee KG, Conway SP et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros 2003; 2: 29-34.
7. Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust's Antibiotic Group, April 2000.
8. Aaron SD, Vandenheem KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-71.
9. Taylor RF, Hodson ME. Cystic fibrosis: Antibiotic prescribing practices in the United Kingdom and Eire. Respir Med 1993; 87: 535-9.
10. Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 2004; 53: 609-15.